share_log

Sabra Health Care REIT Analyst Ratings

Sabra Health Care REIT Analyst Ratings

Sabra 医疗保健房地产投资信托基金分析师评级
Benzinga ·  2023/10/17 07:17
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/17/2023 11.11% BMO Capital → $16 Downgrades Outperform → Market Perform
10/16/2023 4.17% Wells Fargo → $15 Upgrades Underweight → Equal-Weight
10/10/2023 — B of A Securities Upgrades Neutral → Buy
10/03/2023 11.11% Wedbush → $16 Initiates Coverage On → Outperform
09/20/2023 4.17% Jefferies $11 → $15 Upgrades Hold → Buy
08/11/2023 -2.78% B of A Securities $11 → $14 Upgrades Underperform → Neutral
07/27/2023 -9.72% Berenberg → $13 Initiates Coverage On → Hold
07/14/2023 -13.19% Citigroup $11 → $12.5 Maintains Neutral
04/25/2023 -9.72% Barclays $15 → $13 Maintains Equal-Weight
04/20/2023 -23.61% Wells Fargo → $11 Initiates Coverage On → Underweight
04/19/2023 -23.61% Wells Fargo → $11 Initiates Coverage On → Underweight
04/12/2023 -9.72% Credit Suisse → $13 Reiterates → Neutral
03/29/2023 -9.72% Truist Securities $14 → $13 Maintains Buy
03/28/2023 -27.08% Citigroup $13 → $10.5 Maintains Neutral
12/13/2022 — JMP Securities Downgrades Market Outperform → Market Perform
11/14/2022 -9.72% B of A Securities $15 → $13 Downgrades Neutral → Underperform
10/10/2022 -9.72% Baird → $13 Downgrades Outperform → Neutral
06/30/2022 -2.78% Jefferies $15 → $14 Downgrades Buy → Hold
05/25/2022 4.17% Mizuho $16 → $15 Upgrades Neutral → Buy
04/18/2022 -2.78% Barclays $16 → $14 Downgrades Overweight → Equal-Weight
04/04/2022 4.17% Credit Suisse $14 → $15 Maintains Neutral
03/11/2022 4.17% B of A Securities → $15 Upgrades Underperform → Neutral
02/23/2022 25% Stifel $21 → $18 Maintains Buy
02/18/2022 — Keybanc Initiates Coverage On → Sector Weight
02/01/2022 -2.78% Credit Suisse → $14 Initiates Coverage On → Neutral
09/30/2021 25% Truist Securities → $18 Upgrades Hold → Buy
09/13/2021 38.89% JMP Securities $24 → $20 Maintains Market Outperform
05/21/2021 45.83% BMO Capital $20 → $21 Upgrades Market Perform → Outperform
05/10/2021 45.83% Stifel $17 → $21 Upgrades Hold → Buy
01/13/2021 38.89% Jefferies $17 → $20 Upgrades Hold → Buy
01/08/2021 31.94% BMO Capital → $19 Upgrades Underperform → Market Perform
12/03/2020 66.67% JMP Securities → $24 Upgrades Market Perform → Market Outperform
09/02/2020 4.17% Stifel → $15 Reinstates → Hold
06/23/2020 4.17% Scotiabank $12 → $15 Upgrades Sector Underperform → Sector Perform
06/22/2020 -2.78% Wells Fargo $13 → $14 Maintains Equal-Weight
05/18/2020 4.17% Berenberg → $15 Upgrades Hold → Buy
04/23/2020 — SunTrust Robinson Humphrey Maintains Hold
04/07/2020 -30.56% Citigroup $20 → $10 Maintains Neutral
03/26/2020 -27.08% Wells Fargo $22 → $10.5 Maintains Equal-Weight
02/26/2020 52.78% Mizuho → $22 Upgrades Neutral → Buy
02/06/2020 73.61% Barclays $26 → $25 Maintains Overweight
02/05/2020 52.78% Berenberg → $22 Initiates Coverage On → Hold
12/20/2019 52.78% Mizuho → $22 Initiates Coverage On → Neutral
12/18/2019 — Citigroup Upgrades Sell → Neutral
10/14/2019 — B of A Securities Reinstates → Neutral
09/27/2019 59.72% JMP Securities $22 → $23 Maintains Market Outperform
09/23/2019 38.89% Citigroup $18 → $20 Downgrades Neutral → Sell
09/03/2019 66.67% Barclays → $24 Initiates Coverage On → Overweight
02/26/2019 — BMO Capital Downgrades Market Perform → Underperform
12/17/2018 31.94% Wells Fargo $23 → $19 Maintains Market Perform
11/16/2018 45.83% B of A Securities $23 → $21 Downgrades Neutral → Underperform
11/16/2018 — Raymond James Downgrades Outperform → Market Perform
11/13/2018 45.83% Mizuho → $21 Downgrades Buy → Neutral
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
10/17/2023 11.11% 蒙特利尔银行资本 →$16 评级下调 跑赢→市场表现
10/16/2023 4.17% 富国银行 →$15 升级 重量不足的→等重
2023年10月10日 - B of A证券 升级 中性→购买
10/03/2023 11.11% 韦德布什 →$16 开始承保 →跑赢大盘
09/20/2023 4.17% 杰富瑞 $11→$15 升级 持有→购买
2023年08月11日 -2.78% B of A证券 $11→$14 升级 表现不佳的→中性
07/27/2023 -9.72% 贝伦伯格 →$13 开始承保 →保留
07/14/2023 -13.19% 花旗集团 $11→$12.5 维护 中性
04/25/2023 -9.72% 巴克莱 $15→$13 维护 等重
04/20/2023 -23.61% 富国银行 →$11 开始承保 →减持
04/19/2023 -23.61% 富国银行 →$11 开始承保 →减持
04/12/2023 -9.72% 瑞士信贷 →$13 重申 →中性
03/29/2023 -9.72% Truist证券 $14→$13 维护 买
03/28/2023 -27.08% 花旗集团 $13→$10.5 维护 中性
2022年12月13日 - JMP证券 评级下调 市场表现优于→市场表现
2022年11月14日 -9.72% B of A证券 $15→$13 评级下调 中性→表现不佳
2022年10月10日 -9.72% 贝尔德 →$13 评级下调 跑赢→中性
2022/06/30 -2.78% 杰富瑞 $15→$14 评级下调 购买→Hold
2022年05月25日 4.17% 瑞穗 $16→$15 升级 中性→购买
04/18/2022 -2.78% 巴克莱 $16→$14 评级下调 超重→等重
04/04/2022 4.17% 瑞士信贷 $14→$15 维护 中性
03/11/2022 4.17% B of A证券 →$15 升级 表现不佳的→中性
02/23/2022 25% Stifel $21→$18 维护 买
02/18/2022 - KeyBanc 开始承保 →行业权重
02/01/2022 -2.78% 瑞士信贷 →$14 开始承保 →中性
09/30/2021 25% Truist证券 →$18 升级 持有→购买
09/13/2021 38.89% JMP证券 $24→$20 维护 市场表现强于大盘
2021/05/21 45.83% 蒙特利尔银行资本 $20→$21 升级 市场表现优于→
2021/05/10 45.83% Stifel $17→$21 升级 持有→购买
2021/01/13 38.89% 杰富瑞 $17→$20 升级 持有→购买
01/08/2021 31.94% 蒙特利尔银行资本 →$19 升级 表现逊于→市场表现
12/03/2020 66.67% JMP证券 →$24 升级 市场表现优于→市场表现
09/02/2020 4.17% Stifel →$15 恢复 →保留
2020/06/23 4.17% 加拿大丰业银行 $12→$15 升级 行业表现逊于→行业表现
06/22/2020 -2.78% 富国银行 $13→$14 维护 等重
05/18/2020 4.17% 贝伦伯格 →$15 升级 持有→购买
04/23/2020 - SunTrust Robinson Humphrey 维护 保持
04/07/2020 -30.56% 花旗集团 $20→$10 维护 中性
03/26/2020 -27.08% 富国银行 $22→$10.5 维护 等重
02/26/2020 52.78% 瑞穗 →$22 升级 中性→购买
02/06/2020 73.61% 巴克莱 $26→$25 维护 超重
02/05/2020 52.78% 贝伦伯格 →$22 开始承保 →保留
2019年12月20日 52.78% 瑞穗 →$22 开始承保 →中性
2019年12月18日 - 花旗集团 升级 卖出→中性
2019年10月14日 - B of A证券 恢复 →中性
2019年09月27日 59.72% JMP证券 $22→$23 维护 市场表现强于大盘
2019年09月23日 38.89% 花旗集团 $18→$20 评级下调 中性→销售
2019年09月03日 66.67% 巴克莱 →$24 开始承保 →超重
2019年02月26日 - 蒙特利尔银行资本 评级下调 市场表现→表现不佳
2018年12月17日 31.94% 富国银行 $23→$19 维护 市场表现
2018年11月16日 45.83% B of A证券 $23→$21 评级下调 中性→表现不佳
2018年11月16日 - 雷蒙德·詹姆斯 评级下调 跑赢→市场表现
2018年11月13日 45.83% 瑞穗 →$21 评级下调 购买→中性

What is the target price for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的目标价格是多少？

The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by BMO Capital on October 17, 2023. The analyst firm set a price target for $16.00 expecting SBRA to rise to within 12 months (a possible 11.11% upside). 16 analyst firms have reported ratings in the last year.

蒙特利尔银行资本于2023年10月17日报告了Sabra Health Care REIT(纳斯达克：SBRA)的最新目标价。这家分析公司将目标价定为16.00美元，预计SBRA将在12个月内上涨(可能上涨11.11%)。过去一年，有16家分析公司公布了评级。

What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的最新分析师评级是多少？

The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by BMO Capital, and Sabra Health Care REIT downgraded their market perform rating.

蒙特利尔银行资本提供了对Sabra Health Care REIT(纳斯达克代码：SBRA)的最新分析师评级，Sabra Health Care REIT下调了其市场表现评级。

When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Sabra Health Care REIT的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sabra Health Care REIT的上一次评级是在2023年10月17日提交的，因此您应该预计下一次评级将在2024年10月17日左右的某个时候提供。

Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?

分析师对Sabra Health Care REIT(SBRA)的评级正确吗？

While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a downgraded with a price target of $0.00 to $16.00. The current price Sabra Health Care REIT (SBRA) is trading at is $14.40, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Sabra Health Care REIT(SBRA)评级被下调，目标价为0.00美元至16.00美元。Sabra Health Care REIT(SBRA)目前的交易价格为14.40美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发